Hypercoagulability

Hypercoagulability, also known as thrombophilia, is a clinical condition characterized by an abnormally increased tendency for blood to clot within the vascular system (StatPearls, 2023). It is not a specific molecular target (such as a single receptor or enzyme) but rather a complex physiological state resulting from an imbalance between procoagulant and anticoagulant factors (PubMed, 2021). This prothrombotic state can be inherited, such as through Factor V Leiden or Protein C deficiency, or acquired due to factors like malignancy, pregnancy, or prolonged immobilization (Mayo Clinic, 2023). The condition significantly increases the risk of life-threatening events, including deep vein thrombosis (DVT), pulmonary embolism (PE), and stroke. Therapeutic management focuses on using anticoagulant drugs that target specific enzymes within the coagulation cascade, such as Factor Xa or Thrombin (Factor IIa), to prevent thrombus formation and maintain vascular patency (PubChem, 2024).

Other names

ThrombophiliaProthrombotic stateHypercoagulable stateClotting disorder

Pharmacological intervention aims to inhibit key proteases in the coagulation cascade (specifically Factor Xa and Thrombin) to decrease fibrin formation and prevent the propagation of blood clots (PubChem, 2024).